Look Kirk 4

What Happened
Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc. (ONCY), received a grant of 260,000 derivative equity awards on June 1, 2026. The Form 4 reports the award as 260,000 shares at $0.00 (derivative); a footnote clarifies the exercise price equals the closing price of ONCY common stock on Nasdaq on the grant date, so the award had no immediate intrinsic value. This was a compensatory equity grant (neither a cash purchase nor a sale).

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (appears filed within the usual two-business-day window).
• Reported amount: 260,000 derivative shares/options; reported price $0.00 on the form.
• Vesting: Award vests in three equal annual installments; first tranche vests June 1, 2027, subject to continued service. (Footnotes F1–F2)
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — exercise price = closing Nasdaq price on June 1, 2026; F2 — three-year annual vesting schedule.
• Transaction type code: A (award/grant); derivative instrument rather than an open-market purchase.

Context
This is a routine executive equity compensation grant that vests over time and does not provide immediate cash or realized gain because the exercise price was set at the market closing price on the grant date. Such grants align executive pay with shareholder value over the vesting period but are not direct buy/sell signals by the insider.